Preclinical News and Research

RSS

Americans come up with first swine flu vaccine

The company based in Connecticut, Protein Sciences Corporation, won a $35-million government contract to develop an influenza vaccine using insect cell technology and Protein Sciences's director Dan Adams says the first batch of about 100,000 doses were produced last week and the manufacture of the vaccine continues.

24 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

New diagnostic technique detects possible Alzheimer's biomarker in blood

A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH).

17 Jun 2009

Distributed drug discovery for neglected diseases

Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease.

16 Jun 2009

Discovery of key molecular target in age-related macular degeneration

A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults.

15 Jun 2009

Discovery of four new breast cancer targets

Four suspects often found at the scene of the crime in cancer are guilty of the initiation and progression of breast cancer in mice that are resistant to the disease, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the June edition of Cancer Cell.

10 Jun 2009

Discovery of new angiogenesis protein - possible cancer drug target

To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.

9 Jun 2009

New imaging technique: toward spinal cord regeneration?

The axon is a part of the neuron through which nerve impulses are transmitted, and at the end of which is located the synapse, which connects it to another neuron. In the event of a lesion, the axon is the component which must be regenerated in order to restore the connections between the different neurons and re-form the nerve.

5 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Simple MRI test involving breathing oxygen helps determine cancer therapy success

A simple magnetic resonance imaging (MRI) test involving breathing oxygen might help oncologists determine the best treatment for some cancer patients, report researchers at UT Southwestern Medical Center.

3 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

ImmunoVaccine Technologies partners with FIT Biotech to advance therapeutic HIV vaccine

ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, announced a research partnership with FIT Biotech, a Finland-based , clinical stage company that develops DNA vaccines. This research will formulate FIT Biotech's GTU MultiHIV DNA plasmid with IVT's DepoVax vaccine delivery system to advance a therapeutic HIV vaccine.

26 May 2009

Viral Genetics issued patent for novel cancer therapies

Biotechnology firm Viral Genetics, Inc. has been issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710. Additional patents directed at generic classes of the drugs are still pending.

22 May 2009

ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA

ChemGenex Pharmaceuticals Limited announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

21 May 2009

NIH to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

20 May 2009

Cancer Research UK and Glaxosmithkline join forces to trial new anti-cancer drug

Cancer Research UK and Cancer Research Technology (CRT) today announced they will begin a phase I clinical trial of an anti-cancer drug from GlaxoSmithKline (GSK).

19 May 2009

Resverlogix files two patents on compounds for inflammatory diseases

Resverlogix Corp. has announced today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases.

19 May 2009

Biovail acquires worldwide rights to Tetrabenazine

Biovail Corporation today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine tablets), and the associated intellectual property rights held by Cambridge Laboratories (Ireland) Ltd and its affiliates.

18 May 2009

Discovery of molecular pathway behind invasive prostate cancers

University of Cincinnati (UC) cancer and cell biologists have identified a new molecular pathway key to the development of invasive prostate cancers.

18 May 2009

Sodium channel-blocking agent shows promise as a potential treatment for cystic fibrosis

Cystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to researchers at Parion Sciences in Durham, N.C.

17 May 2009